skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: AGN has received a $188.24/s stock+cash offer from ABBV, yet (pre-market) its shares aren't breaking above $173. In this sort of situation, isn't it more typical for the share price to overshoot the offer (given the chance of another bid)? Or is the market doubtful that any deal will be completed?
Read Answer Asked by John on June 25, 2019
Q: Hi 5i,
I have some USD set aside to purchase Pfizer (PFE:US) and have a window of up until about Aug.5th give or take, having missed the latest dividend. So, I am in no real hurry. My question is: should I just proceed and purchase now or wait to see if there is any kind of pull-back presenting a better entry point between now and August? I see it has continued to grind higher over the past while.
Your thoughts would be appreciated.
Thanks!!
Cheers,
Mike
Read Answer Asked by Mike on June 25, 2019
Q: Are you aware of any public sources for the beta coefficient of Canadian listed common stocks?

Thank you for considering my question
Read Answer Asked by Gail on June 25, 2019
Q: Hi there, I had asked a question earlier and you had suggested TEAM as an alternative to SLACK. After doing some searches in the Q&A section it seems like AYX and TEAM are very favourable. Would you be comfortable taking a small position in both names at current prices? Also, are these 2 names your current favourite US growth names? Thanks!
Read Answer Asked by Michael on June 25, 2019
Q: Hi,

Would you consider doing a report on AT-Acuity Ads? Your analysis on this stock is much appreciated. How is their balance sheet, cash flow, debt level, management and their product. Peter's article in the Financial Post got me interested in AT because I sold TTD rather prematurely (and I am kicking myself) ..Would you recommend one to buy the same stock (TTD) at a higher price or consider its little brother?
Read Answer Asked by Shyam on June 24, 2019
Q: What is 5i's thoughts about Sangoma's bought deal financing announced this morning at $1.55. Despite the dilution is it good for current shareholders given the Company's track record? Will it improve valuation metrics (trading multiples) going forward? Currently Sangoma trades less then 1X sales which seems very cheap against their peer group and other small caps.
Read Answer Asked by Charles on June 24, 2019
Q: looking to add Asian exposure in developed countries to my portfolio via an indexed fund . Suggestions please .
Read Answer Asked by darcy on June 24, 2019
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!